The company has received the approval from DCGI for the generic version of Daclatasvir tablets in the strengths of 30 mg and 60 mg, Hetero said in a statement.
The company's product is generic version of Bristol-Myers Squibb's Daklinza tablets, it added.
"The product in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infection, which is highly prevalent in India," Hetero said.
The company has some 25 manufacturing facilities worldwide and its portfolio includes over 200 products in therapeutic categories such as HIV/AIDS, cardiovascular, oncology, neurology and hepatitis.